文献速递骨软组织肉瘤与黑色素瘤

循环肿瘤DNA预测转移性黑色素瘤抗PD1抗体治疗反应

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
PubMed 文献 · Ann Oncol · 2017-01-01

本研究评估转移性黑色素瘤患者接受PD1抑制剂单药或联合伊匹木单抗治疗时,治疗前及治疗早期循环肿瘤DNA(ctDNA)与疗效的关系。基线ctDNA可检测者占53%(40/76),持续升高的患者RECIST缓解率仅6%(1/18),无进展生存期2.7个月、总生存期9.2个月,显著差于基线不可测或早期转阴者;验证队列(n=29)证实ctDNA对缓解的预测价值(P<0.01)。

要点

  • 基线ctDNA可检测与分期、LDH水平、疾病体积及ECOG体力状态相关。
  • 治疗期间ctDNA持续升高的患者缓解率仅6%,中位PFS 2.7个月、OS 9.2个月。
  • 基线ctDNA不可测或治疗12周内转阴者中位PFS和OS均未达到。

核心结论

  • 转移性黑色素瘤患者接受PD1抑制剂治疗时,纵向评估ctDNA可准确预测肿瘤缓解、PFS和OS。
  • 治疗期间ctDNA持续升高的患者预后差,可能有助于指导后续治疗的联合与序贯。

研究设计与样本

  • 研究评估转移性黑色素瘤患者接受PD1抑制剂单药或联合伊匹木单抗治疗前及治疗早期ctDNA与结局的关系。
  • 基线共检测76例患者,另设验证队列29例。

主要发现

  • 基线ctDNA可检测者为40/76例(53%),与分期、LDH水平、疾病体积及ECOG体力状态相关。
  • RECIST缓解率:A组(基线ctDNA不可测)72%(26/36),B组(基线ctDNA升高但治疗12周内转阴)77%(17/22),C组(基线ctDNA升高且治疗期间持续升高)6%(1/18)。
  • 中位PFS:A组和B组未达到,C组2.7个月(A组 vs C组 HR 0.09,P<0.001;B组 vs C组 HR 0.16,P<0.001)。
  • 中位OS:A组和B组未达到,C组9.2个月(A组 vs C组 HR 0.02,P<0.001;B组 vs C组 HR 0.14,P<0.001)。
  • 校正LDH、体力状态、肿瘤分期和疾病体积后,C组不良结局在多因素分析中仍显著;ctDNA对缓解的预测价值在验证队列(n=29,P<0.01)中得到证实。

临床怎么用

  • 原文结论认为纵向评估ctDNA可准确预测转移性黑色素瘤患者接受PD1抑制剂治疗的肿瘤缓解、PFS和OS。
  • 原文指出治疗期间ctDNA持续升高的患者预后差,可能有助于指导后续治疗的联合与序贯。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Programmed death 1 (PD1) inhibitors are now a foundation of medical management of metastatic melanoma. This study sought to determine whether circulating tumour DNA (ctDNA) provides useful early response and prognostic information. PATIENTS AND METHODS: We evaluated the relationship between pre-treatment and early on treatment ctDNA and outcome in melanoma patients treated with PD1 inhibitors alone or in combination with ipilimumab. RESULTS: ctDNA was detected in 40/76 patients (53%) at baseline, and correlated with stage, LDH levels, disease volume and ECOG performance. RECIST response was 72% (26/36) in group A (undetectable ctDNA at baseline), 77% (17/22) in group B (elevated ctDNA at baseline but undetectable within 12 weeks of therapy) and 6% (1/18) in group C (elevated ctDNA at baseline and remained elevated during treatment). The median PFS was not reached in groups A and B and was 2.7 months for group C [hazard ratio (HR) 0.09; P < 0.001 for group A versus C, and 0.16; P < 0.001 for group B versus C]. The median OS was not reached for groups A and B and was 9.2 months for group C (HR 0.02; P < 0.001 for group A versus C and 0.14; P < 0.001 for group B versus C). The poor outcome measures associated with group C remained significant in multivariate analysis adjusted for LDH, performance status, tumour stage and disease volume. The predictive value for ctDNA for response was confirmed in a separate validation cohort (n = 29, P < 0.01). CONCLUSION: Longitudinal assessment of ctDNA in metastatic melanoma patients receiving treatment with PD1 inhibitors is an accurate predictor of tumour response, PFS and OS. Patients who had a persistently elevated ctDNA on therapy had a poor prognosis, and this may guide combination and sequencing of subsequent therapies.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Lee JH, Long GV, Boyd S, et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol. 2017. PMID: 28327969. doi:10.1093/annonc/mdx026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。